1-Phenoxyundecan-2-ol

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 1-Phenoxyundecan-2-ol
• 化学式: C₁₇H₂₈O₂
• 分子量: 264.4
• InChiKey: IICMGWMCYFDEND-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.8
• 重原子数：
  19
• 可旋转键数：
  11
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.65
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• Polymerizable compositions and in-mold cured products using same
  申请人：Takemoto Yushi Kabushiki Kaisha

  公开号：EP0609598A1

  公开（公告）日：1994-08-10

  A polymerizable composition contains unsaturated urethane shown by Formula (1) given below, vinyl monomer which is copolymerizable with this unsaturated urethane, and an inorganic powder filler at weight ratio of (unsaturated urethane)/(vinyl monomer) = 10/90-90/10, the inorganic powder filler being 30-300 weight parts with respect to 100 weight parts of the sum of the unsaturated urethane and vinyl monomer: where X is a residual group obtained by removing isocyanate groups from polyisocyanate; Y is a residual group obtained by removing hydroxyl groups from polyol; R¹ is a residual group obtained by removing hydroxyl group from non-radical polymerizable mono-ol having aliphatic hydrocarbon group with 6-22 carbon atoms; R² is H or CH₃; and p, q and r are each an integer 1-3 such that 2 ≦ p + q ≦ 4 and qr ≧ 2. In-mold cured products obtained from such a polymerizable composition have superior external appearance and water-resistance, and their mold shrinkage is small.

  一种可聚合组合物包含如下式（1）所示的不饱和聚氨酯、可与该不饱和聚氨酯共聚的乙烯基单体和无机粉末填料（重量比为（不饱和聚氨酯）/（乙烯基单体）=10/90-90/10），其中无机粉末填料相对于 100 重量份的不饱和聚氨酯和乙烯基单体之和为 30-300 重量份： 其中，X 是通过从多异氰酸酯中去除异氰酸酯基团而获得的残余基团；Y 是通过从多元醇中去除羟基而获得的残余基团；R¹ 是通过从具有 6-22 个碳原子的脂族烃基的非辐射可聚合单醇中去除羟基而获得的残余基团；R² 是 H 或 CH₃；p、q 和 r 分别是 1-3 的整数，使得 2 ≦ p + q ≦ 4 和 qr ≧ 2。由这种可聚合组合物制成的模内固化产品具有出色的外观和防水性能，而且模具收缩率小。
• Stable denaturants for use in electrophoretic techniques and methods of using the same
  申请人：FMC CORPORATION

  公开号：EP0809103A2

  公开（公告）日：1997-11-26

  This invention presents, inter alia, a class of high power denaturants that are stable in aqueous environments and can be used in electrophoretic techniques such as DNA sequencing and related techniques. The denaturants and electrophoretic media of the invention provide a basis for the high resolution analysis of biological molecules. The denaturants of the invention are also believed to be suitable for electrophoresis of DNA, RNA, proteins, and other macromolecules.

  本发明特别提出了一类在水环境中稳定的高能变性剂，可用于 DNA 测序等电泳技术及相关技术。本发明的变性剂和电泳介质为生物分子的高分辨率分析提供了基础。据信，本发明的变性剂也适用于 DNA、RNA、蛋白质和其他大分子的电泳。
• LAMINATED FILM
  申请人：Toray Industries, Inc.

  公开号：EP3050701A1

  公开（公告）日：2016-08-03

  A laminated film including a support substrate and a surface layer on at least one surface of the support substrate, the laminated film satisfying the following Conditions 1 to 3: Condition 1: the surface layer has a maximum displacement amount in a thickness direction of 1.50 µm or more, and the surface layer has a permanent displacement amount in the thickness direction of not more than 1.30 µm, as determined by a load-unload test method using a micro hardness tester under conditions of a maximum load of 0.5 mN and a retention time of 10 seconds; Condition 2: the surface layer has a relative storage elastic modulus at 100°C, as determined by a rigid body pendulum test method, that is higher than the relative storage elastic modulus at 25°C of the surface layer; and Condition 3: the surface layer has an elongation at break at 150°C, as determined by a tensile test method, of 50% or more. Provided is a laminated film satisfying formability, self-healing properties, design properties, and resistance to high shear.

  一种层压薄膜，包括支撑基板和至少位于支撑基板的一个表面上的表面层，该层压薄膜满足以下条件1至3： 条件1：表面层在厚度方向上的最大位移量为1.50微米或更大，并且表面层在厚度方向上的永久位移量不超过1.条件 1：表层在厚度方向上的最大位移量不超过 1.50 µm，表层在厚度方向上的永久位移量不超过 1.30 µm，该永久位移量是在最大载荷为 0.5 mN 和保持时间为 10 秒的条件下使用显微硬度计通过加载-卸载测试法测定的；条件 2：表层在 100°C 时的相对存储弹性模量（通过刚体摆锤测试法测定）高于表层在 25°C 时的相对存储弹性模量；以及条件 3：表层在 150°C 时的断裂伸长率（通过拉伸测试法测定）大于等于 50%。本发明提供的层压薄膜具有良好的成型性、自愈性、设计性和抗高剪切力。
• WAVELENGTH CONVERSION FILM, WAVELENGTH CONVERSION FILM FORMING COMPOSITION, AND CLUSTER-CONTAINING QUANTUM DOT PRODUCTION METHOD
  申请人：TOKYO OHKA KOGYO CO., LTD.

  公开号：EP3998324A1

  公开（公告）日：2022-05-18

  The objective of the invention is to provide a wavelength conversion film demonstrating a high optical density, a wavelength conversion film forming composition used suitably for forming the wavelength conversion film, and a production method for a cluster-containing quantum dot that may be applied suitably to the wavelength conversion film and the wavelength conversion film forming composition. In this invention, for a wavelength conversion film containing a quantum dot converting blue light into red light or green light, the light beam transmittance of the wavelength conversion film at 450 nm wavelength is set to 40% or lower, the light beam transmittance of the wavelength conversion film at 650 nm wavelength is set to 90% or higher if the hue of the light beam after the wavelength conversion is red, and the light beam transmittance of the wavelength conversion film at 550 nm wavelength is set to 90% or higher if the hue of the light beam after the wavelength conversion is green.

  本发明的目的是提供一种具有高光密度的波长转换膜、一种适合用于形成该波长转换膜的波长转换膜形成组合物，以及一种可适合应用于该波长转换膜和波长转换膜形成组合物的含团簇量子点的生产方法。在本发明中，对于含有将蓝光转换成红光或绿光的量子点的波长转换薄膜，波长为 450 nm 的波长转换薄膜的光束透过率设定为 40% 或更低、如果波长转换后的光束色调为红色，则波长 650 nm 处的波长转换薄膜的光束透射率设定为 90% 或更高，如果波长转换后的光束色调为绿色，则波长 550 nm 处的波长转换薄膜的光束透射率设定为 90% 或更高。
• Modulation of therapeutic agent release from a polymeric carrier using solvent-based techniques
  申请人：——

  公开号：US20030203000A1

  公开（公告）日：2003-10-30

  A method of modulating a rate of release of a therapeutic agent from a medical device is provided. The method comprises: (a) providing a solution comprising a therapeutic agent, a polymer and a solvent system; and (b) forming a therapeutic-agent-loaded polymeric carrier for the medical device by evaporating the solvent system, such that the rate of release is modulated by changing the composition of the solvent system. The composition of the solvent system can be changed in a number ways, including adding solvent species to the solvent system, removing solvent species from the solvent system, both adding and removing solvent species from the solvent system. The solvent system can also be changed by varying the ratio of solvent species within the solvent system.

  本发明提供了一种调节医疗器械中治疗剂释放速率的方法。该方法包括：(a) 提供由治疗剂、聚合物和溶剂系统组成的溶液；(b) 通过蒸发溶剂系统形成用于医疗设备的治疗剂负载聚合物载体，从而通过改变溶剂系统的组成来调节释放速率。改变溶剂体系组成的方式有多种，包括向溶剂体系中添加溶剂种类、从溶剂体系中移除溶剂种类、同时从溶剂体系中添加和移除溶剂种类。还可以通过改变溶剂系统内溶剂种类的比例来改变溶剂系统。